Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, announced the closing of a registered direct offering that generated gross proceeds of approximately $2.0 million. The company sold 7,142,858 shares of common stock pursuant to a securities purchase agreement.
D. Boral Capital LLC acted as the exclusive placement agent for the offering, which was conducted under the company's effective shelf registration statement on Form S-3, declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. The offering provides Jupiter with additional capital to advance its therapeutic pipeline, including its lead program JOTROL, a proprietary enhanced bioavailability resveratrol formulation currently in a Phase IIa clinical trial for Parkinson's disease.
Jupiter also commercializes Nugevia, a consumer longevity supplement, and recently acquired the U.S. rights to ALA-002, a next-generation, patented psychedelic new chemical entity. This acquisition strengthens the company's CNS pipeline at a pivotal moment in U.S. regulatory policy regarding psychedelic therapies.
The completion of this offering is significant for Jupiter as it provides funding to support ongoing clinical trials and operational expenses. For investors, the offering signals continued progress in the company's development of treatments for CNS disorders, a market with substantial unmet medical needs. Parkinson's disease alone affects nearly 1 million people in the United States, and effective treatments remain limited.
More details on the offering can be found in the full press release at https://ibn.fm/o5A0w. For more information about Jupiter Neurosciences, visit www.jupiterneurosciences.com.
